Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A first-in-class oral therapy is turning heads in ulcerative colitis treatment. OD-001, a RIPK2 scaffolding inhibitor, hit its primary endpoint in a phase 2a trial, delivering a 27% clinical remission rate at 12 weeks in patients who had already failed conventional or advanced therapies — with no significant safety concerns. A larger phase 2b trial is now on the horizon.
A novel oral drug is showing real promise for patients with ulcerative colitis who've run out of options. OD-001, developed by Odyssey Therapeutics, is the first-in-class RIPK2 scaffolding inhibitor — a brand-new mechanism of action — and it just cleared a key hurdle in a phase 2a trial presented at United European Gastroenterology Week. The drug significantly improved modified Mayo Clinic Scores from baseline to 12 weeks, meeting its primary endpoint across all patient groups.
The trial enrolled adults with moderately to severely active ulcerative colitis who had inadequate responses or intolerances to existing therapies. The 20 mg twice-daily dose outperformed lower doses across nearly all secondary endpoints, with symptomatic remission kicking in as early as week 2. The drug was well-tolerated throughout.
By the Numbers:
Why it matters: For UC patients who've exhausted current treatment options, a new mechanism of action could be a game-changer. OD-001 is now advancing into phase 2b development — both as a monotherapy and in combination with vedolizumab — keeping hopes alive for a fresh therapeutic avenue.